Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $67.00 to $50.00.
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyBusiness Wire
- Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceBusiness Wire
ATRA
Earnings
- 3/28/24 - Beat
ATRA
Sec Filings
- 3/18/24 - Form SC
- 3/6/24 - Form 4
- 3/6/24 - Form 4
- ATRA's page on the SEC website